An observational study in Neurodegenerative Diseases and Dementia, sponsored by Monash University. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Monash University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Neurodegenerative Diseases with a site in Australia — 6 open to participants now, 12 under way, 2 of them phase 3. Neurodegenerative Diseases · Australia.
Among the 31 studies in Neurodegenerative Diseases with a site in Australia, this one is one of 3 that started in 2021, is one of 2 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 23rd registered.
436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.
Browse Neurodegenerative Diseases studies →6 of the 31 studies in Neurodegenerative Diseases with a site in Australia are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, United States, New Zealand and 1 more country
Ages 50–85
Friedreich's Ataxia Research Alliance · Sites in Australia, United States, Austria and 14 more countries
Healthy volunteers
Center for Eye Research Australia · Sites in Australia
Ages 30+ · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in Australia, United States, Belgium and 5 more countries
Ages 18+
Brain Trust Bio · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 12
First in 2009; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 186 across 156 observational studies indexed under Neurodegenerative Diseases.
Median enrollment 310 across the 29 interventional studies, 2,000 across the 2 observational. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 31 have an industry lead sponsor. The 10 most frequent:
Monash University is the lead sponsor of 83 studies on the registry; 22 are open to participants now.
Monash University has 1 study filed under Neurodegenerative Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Neurodegenerative Diseases with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06339190Monash UniversityNeurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis | 2027-03 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Neurodegenerative Diseases with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.
Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months.
Individuals at risk of a genetic dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.
Problem: There is no "gold-standard test" to detect all forms of dementia. People can present with subtle changes that are missed on standard cognitive screening tests, which are not designed for people whose first language is not English or from diverse cultural and educational backgrounds. State-of-the art brain imaging is only available to Australians living in large urban centres, further entrenching health care inequities. The lack of validated diagnostic tests and pathways causes diagnostic delays, increases patient and caregiver stress. Therapies are on the horizon for many forms of dementia - not only Alzheimer's disease - meaning that the lack of identification of simple dementia diagnostic biomarkers represents a critical knowledge gap.
Mission: New technologies now allow us to test abnormal brain protein levels in a routine peripheral blood test, record a voice sample to analyse its acoustics and reveal brain disease, and perform "mail-out" genetic tests using a simple saliva sample. The levels of a brain derived blood protein, neurofilament light chain (NfL), will be estimated and natural language processing and acoustic analysis will be measured in all patients presenting with cognitive complaints to a single healthcare network servicing 1 million ethnically and culturally diverse Australians. Researchers will investigate the utility of early genetic testing for those at high risk of a genetic cause for their disease. They will use these data to develop diagnostic pathways, leveraging existing collaborations to develop future screening programs. Early to mid-career researchers will be supported to translate new technologies into clinical practice in the shortest practicable time-frame.
Significance: Accessible and cost effective tests will inform new pathways to dementia diagnosis. This will transform the dementia landscape, shortening time to diagnosis, increasing diagnostic certainty, and allowing more Australians access to appropriate care, education, and future therapies.
The study cohort will include any individual of all ages, ethnicities, identities and genders. This is to ensure that the findings are generalisable to other national healthcare networks and to provide maximum information on the utility of using blood-biomarker estimation in real-world clinical settings
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A single blood draw at the time of presentation to clinic or whilst an inpatient.
Baseline NfL level
Plasma Nfl (pg/ml), estimated using Quanterix SIMOA HD-X
Time frame: Day 0
Change in speech processing
Staff and/or self administered using Redenlab software and analysed by speech pathologist for acoustic measures of timing (e.g., pause length (seconds) in reading and monologue tasks), vocal control (e.g., fundamental frequency (hertz) and loudness variation (decibel) from vowel and monologue), and vocal quality (e.g., dysphonia measures derived from sustained vowel).
Time frame: Day 0 and 12-months
Change in language processing
Recorded by a member of the research team using Redenlab software and assessed by a speech therapist using Natural Language Processing techniques.
Time frame: Day 0 and at 12-months
Change in Direct Magnitude Estimation
Perceptual rating of speech using Redenlab software; measuring intelligibility (i.e ability to be understood) and naturalness (deviation from healthy norm) of speech. Assessed by a speech therapist on a scale from 0 to 100; 0 indicates none of the speech is intelligible/natural, 100 indicates all the speech is intelligible/natural.
Time frame: Day 0 and at 12-months
Modified Rankin Scale
Functional screen; assessed by member of the research team based on clinical notes. Assessed as change from baseline. Scores ranging from 0-5, with higher scores indicating greater disability.
Time frame: Day 0 and at 12-months
Montreal Cognitive Assessment score
Cognitive screen; staff administered via telephone. Scores include overall MoCA score (0-22) and Memory Index Score (0-15), greater scores indicate greater cognition.
Time frame: At 12-months
Hospital Anxiety and Depression Scale score
Mood screen; staff administered via telephone. Scores include a total depression score (0-21) and total anxiety score (0-21); grouped according to normal (0-7), Borderline abnormal (8-10) and Abnormal (11-21).
Time frame: At 12-months
Clinical Global Impression score
Global rating of improvement/change; staff administered via telephone. Scored on a 7 point scale, scores closer to 0 indicative of greater improvement and scores closer to 7 representing much worse).
Time frame: At 12-months
WHO Disability Assessment 12-item telephone interview score
Functional screen, staff administered via telephone. Scored as an overall percentage (%) disability, higher scores indicating less function.
Time frame: At 12-months
WHO Disability Assessment 36-item self report score
Functional screen, self administered. Scored as an overall percentage (%) disability, higher scores indicating less function.
Time frame: At 12-months
DNA sample for testing known pathogenic dementia mutations
Self-administered saliva sample; Testing using Invitae Fronto-temporal dementia and AD panel: C9orf72, CHCHD10, CHMP2B, DCTN1, FUS, GRN, HNRNPA2B1, MAPT, SQSTM1, TARDBP, TBK1, TREM2, UBQLN2, VCP, APP, PSEN1 and PSEN2
Time frame: Anytime over the study duration
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Aug 2021 (actual). Primary completion is estimated for Mar 2027, 67 months after the start.
Of 82 observational studies under Neurodegenerative Diseases, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 216. This study's planned 67 months is below that.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Mar 2027, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Monash University